Intech Investment Management LLC Takes Position in Agios Pharmaceuticals, Inc. (NASDAQ:AGIO)

Intech Investment Management LLC purchased a new stake in Agios Pharmaceuticals, Inc. (NASDAQ:AGIO - Free Report) in the 3rd quarter, according to the company in its most recent Form 13F filing with the SEC. The fund purchased 20,078 shares of the biopharmaceutical company's stock, valued at approximately $892,000.

Other hedge funds have also recently added to or reduced their stakes in the company. D. E. Shaw & Co. Inc. lifted its stake in Agios Pharmaceuticals by 87.3% in the second quarter. D. E. Shaw & Co. Inc. now owns 678,234 shares of the biopharmaceutical company's stock valued at $29,245,000 after acquiring an additional 316,100 shares during the last quarter. Seven Eight Capital LP bought a new stake in Agios Pharmaceuticals in the second quarter worth $1,693,000. Edgestream Partners L.P. acquired a new position in Agios Pharmaceuticals during the second quarter worth $1,814,000. Farallon Capital Management LLC raised its holdings in Agios Pharmaceuticals by 1.1% during the second quarter. Farallon Capital Management LLC now owns 5,654,502 shares of the biopharmaceutical company's stock valued at $243,822,000 after buying an additional 63,900 shares in the last quarter. Finally, Tidal Investments LLC acquired a new stake in shares of Agios Pharmaceuticals in the first quarter worth about $946,000.

Insider Buying and Selling

In related news, CFO Cecilia Jones sold 2,542 shares of the stock in a transaction dated Thursday, September 26th. The shares were sold at an average price of $49.03, for a total value of $124,634.26. Following the completion of the transaction, the chief financial officer now owns 20,158 shares of the company's stock, valued at $988,346.74. This represents a 11.20 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available at this hyperlink. 4.93% of the stock is owned by company insiders.

Agios Pharmaceuticals Stock Up 1.2 %

Agios Pharmaceuticals stock traded up $0.73 during trading hours on Friday, hitting $59.39. The stock had a trading volume of 237,613 shares, compared to its average volume of 694,239. Agios Pharmaceuticals, Inc. has a fifty-two week low of $20.96 and a fifty-two week high of $62.58. The company has a market cap of $3.39 billion, a PE ratio of 5.16 and a beta of 0.75. The company has a 50-day moving average of $48.42 and a two-hundred day moving average of $45.23.

Wall Street Analysts Forecast Growth

A number of brokerages recently weighed in on AGIO. Leerink Partners downgraded Agios Pharmaceuticals from an "outperform" rating to a "market perform" rating and cut their price objective for the company from $60.00 to $56.00 in a research note on Friday, September 27th. StockNews.com raised shares of Agios Pharmaceuticals from a "sell" rating to a "hold" rating in a research report on Saturday, November 9th. Cantor Fitzgerald reaffirmed an "overweight" rating on shares of Agios Pharmaceuticals in a report on Friday, September 20th. Raymond James reiterated an "outperform" rating and issued a $51.00 target price on shares of Agios Pharmaceuticals in a report on Thursday, October 10th. Finally, Scotiabank increased their target price on Agios Pharmaceuticals from $51.00 to $53.00 and gave the company a "sector outperform" rating in a research note on Friday, November 1st. Five analysts have rated the stock with a hold rating and four have assigned a buy rating to the company. According to MarketBeat, Agios Pharmaceuticals currently has a consensus rating of "Hold" and a consensus price target of $52.33.

Agios Pharmaceuticals Company Profile

Agios Pharmaceuticals, Inc, a biopharmaceutical company, discovers and develops medicines in the field of cellular metabolism in the United States. Its lead product includes PYRUKYND (mitapivat), an activator of wild-type and mutant pyruvate kinase (PK), enzymes for the treatment of hemolytic anemias.